Your browser doesn't support javascript.
loading
The relationship between brain metastasis and HER2 expression status in gastric cancer
Lai, Ming-Yu; Guan, Wen-Long; Yang, Jing; Sun, Yu-Ting; Qiu, Miao-Zhen; Lu, Shi-Xun; Yang, Li-Qiong; Yang, Da-Jun.
Afiliación
  • Lai, Ming-Yu; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
  • Guan, Wen-Long; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
  • Yang, Jing; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
  • Sun, Yu-Ting; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
  • Qiu, Miao-Zhen; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
  • Lu, Shi-Xun; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
  • Yang, Li-Qiong; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
  • Yang, Da-Jun; Collaborative Innovation Center for Cancer Medicine. State Key Laboratory of Oncology in South China. Guangzhou. China
Clin. transl. oncol. (Print) ; Clin. transl. oncol. (Print);26(3): 765-773, mar. 2024.
Article en En | IBECS | ID: ibc-230806
Biblioteca responsable: ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Background Brain metastasis (BM) in gastric cancer (GC) is underestimated, and human epidermal growth factor receptor 2 (HER2) overexpression is a durable poor prognostic factor. We explored the relationship between the two and made a survival analysis. Methods HER2 expression and BM status were collected from GC patients who were diagnosed between December 2009 and May 2021. We collected GC patients diagnosed between 2010 and 2016 from the SEER database. The primary endpoint was survival from the diagnosis of BM. Multivariable logistic regression was used to determine potential risk factors of BM at diagnosis in SEER database. Survival analysis was performed using the Kaplan–Meier method. Result There were 513 HER2-positive GC patients, including 16 (3.1%) with BM. Among 38 brain metastasis GC patients we collected, 16 (42.1%) patients were HER2 positive. We collected 34,199 GC patients from the SEER database and there were 260 (0.76%) patients with BM at diagnosis. GC patients that are male, white, of younger age, with primary lesions located in the proximal stomach or with distant lymph nodes, liver, bone, or lung metastasis are more likely to develop BM. The median overall survival time from diagnosis of BM was 12.73 months, and the survival time from brain metastasis of HER2-positive patients was numerically shorter, though the difference was not significant (5.30 months vs.16.13 months, P = 0.28.) Conclusion The incidence of BM in patients with HER2-positive gastric cancer is 4.08 times higher than that in general patients. The median overall survival time from BM is shorter for HER2-positive patients (AU)
Asunto(s)
Palabras clave
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Neoplasias Gástricas / Neoplasias Encefálicas / Receptor ErbB-2 Límite: Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2024 Tipo del documento: Article
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Neoplasias Gástricas / Neoplasias Encefálicas / Receptor ErbB-2 Límite: Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2024 Tipo del documento: Article